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0022-2836/$ - see front matter © 2007 EDExD-box helicases are involved in all aspects of cellular RNAmetabolism.
Conserved domains 1 and 2 contain nine signature motifs that are
responsible for nucleotide binding, RNA binding and ATP hydrolysis.
The human DEAD-box helicase DDX3X has been associated with several
different cellular processes, such as cell-growth control, mRNA transport
and translation, and is suggested to be essential for the export of unspliced/
partially spliced HIV mRNAs from the nucleus to the cytoplasm. Here, the
crystal structure of conserved domains 1 and 2 of DDX3X, including a
DDX3-specific insertion that is not generally found in human DExD-box
helicases, is presented. The N-terminal domain 1 and the C-terminal domain
2 both display RecA-like folds comprising a central β-sheet flanked by
α-helices. Interestingly, the DDX3X-specific insertion forms a helical
element that extends a highly positively charged sequence in a loop, thus
increasing the RNA-binding surface of the protein. Surprisingly, although
DDX3X was crystallized in the presence of a large excess of ADP or the
slowly hydrolyzable ATP analogue ATPγS the contaminant AMP was seen
in the structure. A fluorescent-based stability assay showed that the thermal
stability of DDX3X was increased by the mononucleotide AMP but not by
ADP or ATPγS, suggesting that DDX3X is stabilized by AMP and
elucidating why AMP was found in the nucleotide-binding pocket.© 2007 Elsevier Ltd. All rights reserved.*Corresponding author Keywords: DEAD-box; helicase; HIV; RNA; nucleotideIntroduction
RNA-binding DExD-box helicases are ATPases
that function as RNA-unwinding enzymes, chaper-
ones that promote the correct folding of RNAs or
assembly/disassembly factors of protein–RNA
complexes, during all stages of RNA-metabolism.1ter for Biomembrane
try and Biophysics,
ckholm, Sweden.
lly to this work.
er chromatography;
ng author:
lsevier Ltd. All rights reserveDDX3 is a human DEAD-box helicase that is found
in the two closely related forms DDX3X and DDX3Y
(encoded on the X chromosome and Y chromosome
respectively),2 which are 92% identical in sequence.
DDX3Y is produced specifically in spermatocytes,
where it is essential for spermatogenesis.3,4 DDX3X
has been associated with several different cellular
processes, such as cell-growth control,5 transport of
mRNA6 and translation.7,8 Interestingly, during
HIV replication, the transport of unspliced/partially
spliced HIV mRNAs that contain a Rev-responsive
element (RRE) from the nucleus to the cytoplasm is
dependent on the viral protein Rev, shuttling protein
CRM1 (exportin 1) and DDX3X. Rev can be
immunoprecipitated by DDX3X and CRM1, sug-
gesting that the proteins form complex(es), and it
has been proposed that the helicase activity ofd.
151Crystal Structure of Human DDX3XDDX3X enables the threading of HIV mRNAs
through the nuclear pore.9 The involvement of
DDX3X in HIV infection makes it an interesting
candidate for antiviral therapy,10 and it is therefore
important to determine the three-dimensional struc-
ture of the human DDX3X DEAD-box helicase.
The RNA-binding DExD-box proteins belong to
the SF2 superfamily of helicases based on their
primary sequence. Most DExD-box helicases contain
two subdomains (named 1 and 2) that are often
flanked by divergent sequences.1 Nine short con-
sensus sequences that form the conserved helicase
core are found in the two subdomains; motifs Q, I
(Walker A containing the phosphate-binding P-
loop), II (Walker B, DExD-box), Ia, Ib and III are
found in domain 1, whereas motifs IV, V and VI are
found in domain 2. Structural, biochemical and
mutational analysis show that the different motifs
are involved in nucleotide binding (Q, I and II),
RNA binding (Ia, Ib, IV and V) and ATP hydrolysis
(III and possibly VI).1 Structure determination of
individual domains shows that both domains 1 and
2 have a fold belonging to the RecA superfamily
with five β-strands surrounded by five α-helices.1
So far, structures containing both domains, con-
nected via a short flexible linker have been solved of
the human splicing factor UAP56 with/without
ADP,11 human eIF4A-III,12,13 yeast mRNA transla-
tion and degradation factor Dhh1p,14 Methanococcus
jannaschii DEAD-box protein,15 the Drosophila
VASA protein,16 and the eIF4A protein.17 There are
additional structures of domain 1, including eIF4A
from yeast without18,19 or with ADP/ATP bound,19
human UAP56 with a citrate ion bound,20 Dugesia
japonica VASA-like gene B protein,21 BstDEAD,22
and Thermus thermophilus Hera helicase in complex
with AMP or orthophosphate.23 Moreover, a sepa-
rate structure of domain 2 of UAP56 has been
solved.20 The two-domain structures with nucleo-
tide present show its location in a cleft between the
two domains, interacting mainly with domain 1,
with the adenine moiety forming interactions with
amino acid residues in motif I, whereas the γ and β
phosphate groups on the nucleotide interact with
amino acid residues inmotif II through amagnesium
ion.1 The relative orientation of the two domains
varies extensively between the different structures as
long as no RNA substrate is present.11,12,14,15,17 It is
now becoming evident that DExD-box helicases
acquire an active, well defined and closed conforma-
tion upon RNAbinding as observed in the structures
of Drosophila VASA protein and human eIF4AIII in
complex with poly(U).12,13,16 It is seen from the
structures with substrate present that the RNA is
bent upon binding, hinting at possible mechanisms
for helicase activity.12,13,16,24
Recombinant full-length DDX3X produced in
bacteria displays ATPase and RNA-unwinding
activity.9 The full-length protein (662 amino acid
residues) consists of domains 1 and 2 flanked by N
and C-terminal divergent sequences. Interestingly,
there is also a DDX3X (and Y)-specific insertion
between motifs I and Ia (residues 250–259) which isnot generally found in other DExD-box helicases.
Here, we present the structure of domains 1 and 2
in DDX3X comprising the helicase core (residues
V168–G582) in complex with AMP at 2.2 Å resolu-
tion, and reach conclusions about the specific
insertion.Results
A sequence alignment of six different DDX3
orthologues (not shown) shows that human
DDX3X displays a high level of identity with the
mouse PL10 (95%), human DDX3Y (92%) and
Xenopus An3 (85%) proteins, whereas the level of
identity with Drosophila Belle (59%) and yeast
Ded1p (51%) proteins is lower. This alignment
shows that the domain 1 and domain 2 conserved
sequence comprising the helicase core, including the
nine consensus motifs, starts around residue 150
(DDX3X numbering) and ends around residue 550
(DDX3X numbering).
A multiple construct approach was applied to
identify truncated versions of DDX3X, spanning
domains 1 and 2, that are expressed well and
produce soluble protein in a small-scale format
(results not shown). For this purpose, 11 different
constructs of DDX3X were cloned into the pNIC-
Bsa4 vector that encodes a His-tag followed by a
TEV-protease cleavage site immediately upstream of
the inserted gene or gene fragment. Constructs
spanning both domains, starting at V168 or A170
and ending at Y576 or G582, produced soluble
protein in a small-scale format and purified well in a
large-scale format (results not shown). However,
expressed and purified protein starting at A170 in
the DDX3X sequence precipitated during concentra-
tion. In the structure of DDX3X (see below) the
preceding V168 and A169 take part in the formation
of a large β-sheet, explaining why the construct
starting at A170 was unstable after purification.
Instead, two other constructs were pursued, V168–
Y576 and V168–G582. In the end, the best-diffracting
crystals were obtained with the construct spanning
V168-G582. Crystallization trials were performed
without nucleotide and with ADP, ATPγS, ANP and
AMPPCP but crystals were produced only with
ADP and ATPγS. Curiously, the monophosphate
AMP was seen in both of the resulting structures
(see below).
Overall structure
The crystallized construct DDX3X(V168-G582)
could be traced from V168 (a preceding methionine
residue, introduced in the cloning, is also visible in
the density) to Y580. The linker between domain 1
and domain 2 (residues 407–410) and residues 535–
536 and 581–582 of domain 2 are disordered. As
expected, the two-domain structure of DDX3X
(V168-G582) displays the two RecA-like domains
found in other DExD-box RNA helicases.11,12,14,15,17
The N-terminal domain 1 contains the RecA-like
152 Crystal Structure of Human DDX3Xfold comprising a central five-stranded β-sheet
flanked by 5 α-helices. An additional β-strand and
two α-helices form a cap-like structure (residues
167–215) that includes the Q-motif important for
nucleotide binding. Similarly, domain 2 comprises a
RecA-like fold, including a central β-sheet flanked
by α-helices.
Figure 1 shows the structure with domain 1 on the
right and domain 2 on the left, with the consensus
motifs indicated. Compared to the two available
DEAD-box helicase structures with RNA bound
(Drosophila VASA16 and the human eIF4AIII12,13)
DDX3Xdisplays a less compact “open” structurewith
regards to the relative orientation of the domains.
The RNA-bound “closed” form of the proteins
seem to be well defined and dictated by the RNA
binding. Indeed, 359 of the 420 residues from both
domains in the VASA structure can be super-
imposed on the eIF4AIII structure with a Cα rmsd
of below 1.5 Å. The open forms, without RNA
bound, on the other hand display large differences
in the relative orientations between the two domains
and the different proteins for which structures are
available display diverse conformations.11,12,14,15,17
It thus seems that the sequence linking the two
domains provides a very large degree of flexibility.
We find it quite likely that the observed open
structures are defined by monomer–monomer con-
tacts that favor crystallization rather than a single
biologically relevant defined open conformation.
Nucleotide-binding pocket
DDX3X(V168-G582) was co-crystallized with
ATPγS and ADP. In both cases AMP (a contaminant,Figure 1. Overall structure. The consensus motifs are
indicated, the disordered part of the sequence connecting
the two domains is indicated by a broken line.see below) was seen in the electron density map
(Figure 2(a)). The interaction of AMP with amino
acid residues in the nucleotide-binding pocket of
DDX3X(V168-G582) is highly similar to the interac-
tion of AMP with the N-terminal domain of the T.
thermophilus DEAD-box helicase Hera.23 The ade-
nine moiety of the nucleoside interacts with amino
acids in the Q motif, whereas residues in the P-loop
in motif I interact with the phosphate group. In
DDX3X(V168-G582), N6 on the purine interacts with
the backbone carbonyl group of arginine 202 and
with Oε of glutamine 207 in the Q-motif. This
interaction scheme gives selectivity for adenine
nucleotides compared to guanine nucleotides. Nε
of glutamine 207 also interacts with the N7 position
of the adenine. A conserved aromatic ring (tyrosine
200 in DDX3X(V168-G582), otherwise phenylala-
nine or a tryptophan) stacks on the base. The
phenolic oxygen atom also hydrogen bonds to the
2′OH on the ribose. The phosphate group makes
polar interactions with the hydroxyl group on
threonine 231 and to backbone nitrogen atoms of
residues 227–231 in the P-loop in motif I as well as to
three water molecules.
Figure 2(b) shows superpositions of the nucleo-
tide-binding region and DExD-box motif for DDX3X
(V168-G582) (blue), UAP56 with ADP (green) (PDB
code 1XTJ,11 without ligand (magenta) (PDB code
1XTI)11), VASA (red) with the non-hydrolyzable
ATP analogue ANP (PDB code 2DB3),16 yeast Dhhp
(yellow) (PDB code 1S2M)14 and yeast eIF4A (black)
(PDB code 1FUU).17 The AMP molecule from
DDX3X(V168-G582) and ANP from VASA are
shown for reference. It seems that the P-loop does
not adopt distinct open or closed conformations but
has a flexibility that allows it to adapt to several
conformations and sizes of ligands.23 The most
restricted (closed) conformation is found in yeast
eIF4A (black), which leaves no room for a ligand.
The DDX3X(V168-G582) structure with AMP bound
adopts a more open conformation (blue) that is
similar to the UAP56 without any ligand bound
(magenta). UAP56 in complex with ADP (green)
adopts an open conformation that is very similar to
VASAwith a triphosphate ligand (red) and to yeast
Dhhp (yellow) with no ligand bound. The side-
chains of the DExD motif adopt very much the same
conformations, independent of the ligand, the only
conformations that stand out are the two UAP56
structures that display different rotamers of the
glutamate residue in the motif.
RNA-binding surface
The DDX3X(V168-G582) domain 2 has to rotate
approximately 180° relative to domain 1 to obtain
the closed conformation of the protein required for
RNA binding. This rearrangement would bring
positively charged patches on the solvent-exposed
surface of domain 2 into closer proximity with
positively charged surfaces on domain 1, thus
forming the RNA-binding site of the protein. A
comparison of the closed structure of the VASA-
Figure 2. (a) AMP binding in DDX3X(V168-G582),
omit Fo–Fc electron density for the ligand, contoured at
0.14 e/Å3 (4σ). Polar interactions and hydrogen bonds are
indicated by broken lines and water molecules are
represented by red spheres. (b) Superposition of the
nucleotide-binding region with the P-loop and DEAD
motif for DDX3X(V168-G582) (blue), UAP56 with ADP
(green), without nucleotide (magenta), VASA (red), yeast
Dhhp (yellow) and yeast eIF4A (black). The AMP
molecule from DDX3X(V168-G582) (blue) and ANP from
VASA (red) are shown for reference.
153Crystal Structure of Human DDX3Xprotein in complex with poly(U) with a modeled
closed structure of the DDX3X(V168-G582) protein
show that all amino acid residues that are involved
in interaction with the RNA in the VASA-structure
are present in the DDX3X(V168-G582) structure at
corresponding positions. This indicates, as expected,
that these residues are involved in RNA binding in
both proteins, and that the RNA binding mode in
this area should be very similar.
DDX3X has an insertion of ten residues (250–259,
EALRAMKENG) between the P-loop and the RNA-
binding motif Ia. A sequence alignment of 32
different human DExD-box helicases shows that
this striking insertion is seen only in DDX3X and
DDX3Y (Figure 3). The inserted sequence precedes a
positively charged sequence, maintained in the
different DDX3-orthologues.
The insertion forms a helix that packs against the
protein and extends the following highly positively
charged (RYGRRK) loop sequence, also unique to
DDX3X/Y (Figures 3 and 4). Interestingly, this loop,
together with other surface residues on DDX3X
(V168-G582), forms a continuous positively charged
cavity. Amodel of the closedRNA-bound formof the
DDX3X(V168-G582) structure, based on the VASA
structure and its short RNA ligand shows that this
cavity is positioned close to the 3′ end of the RNA. It
seems very likely that this extended patch, which is
found only in the DDX3X/Yproteins, is involved in
RNA binding and positioning in these proteins.
ATP hydrolysis and nucleotide-binding
properties of DDX3X(V168-G582)
Full-length DDX3X hydrolyzes ATP in an RNA-
dependent fashion.9 Surprisingly, DDX3X(V168-
G582) displayed no ATPase activity in the presence
of four different RNA substrates and at several
different conditions tested (results not shown, see
Materials and Methods).Figure 3. Sequence alignment of
32 different human DExD-box heli-
cases covering the conserved region
between motifs I and Ia (amino acid
residues 229–279 in DDX3X) and
showing the DDX3X/Y-specific in-
sertion between residues 250 and259
(red box). Totally conserved/highly
conserved residues are shown in
green.
Figure 4. (a) Superposition of the loop region in the
vicinity of the DDX3-specific insertion, coloring as in
Figure 2(b) and mapped on the DDX3X(V168-G582)
structure (blue). Positively charged residues in the
extended loop in DDX3X(V168-G582) are shown as sticks.
(b) Surface contact potential representation of an RNA-
bound model of DDX3X(V168-G582) (based on the
Drosophila VASA structure). The extended loop creates
an elongated, positively charged cavity positioned close to
one end of the short RNA ligand.
Figure 5. Nucleotide-binding properties of DDX3X
(V168-G582). (a) No detectable AMP was formed when
DDX3X(V168-G582) was incubated with [α-32P]ATP and
nucleotides separated by TLC and detected by autoradio-
graphy/phosphoimager: [α-32P]AMP was run as a com-
parison. (b) Thermofluor stability assays suggest DDX3X
is stabilized by the mononucleotide AMP. The control
shows the thermal shift of DDX3X without added nuc-
leotide, whereas 8 mM nucleotide (final concentration) has
been added to the samples labeled ATP, ADP or AMP,
error bars are based on three to five different experiments.
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20 mM ADP or ATPγS, AMP was found in the
nucleotide-binding pocket of DDX3X(V168-G582) in
the crystallized protein (Figure 2(a)) making DDX3X
the second DEAD-box helicase solved with AMP,
the first being the recently solved domain 1 of Hera
helicase.23 AMP could have been formed by a
phosphotransferase activity, spontaneous degrada-
tion of ADP and ATPγS to AMP or by contaminating
AMP in the nucleotide stocks. To exclude the
possibility that AMP was formed enzymatically by
DDX3X(V168-G582) or contaminating E. coli pro-
teins the DDX3X(V168-G582) preparation was incu-
bated with [α-32P]ATP for 1 h at 37 °C and the
formation of [α-32P]AMPwasmonitored by running
the reaction on thin-layer chromatography (TLC)
plates with [α-32P]AMP as a marker. As can be seen
in Figure 5(a), no formation of AMP could be
detected in the reaction, making it unlikely that aphosphotransferase activity was present in the
DDX3X(V168-G582) preparation. Analysis of the
purity of the ADP by HPLC showed that the ADP
was contaminated with 5% AMP (results not
shown). As a result, approximately 1 mM AMP
was present in the crystallization reaction where
crystals appeared within 24 h, together with
b500 μM protein and a large excess of ADP. Further
HPLC analysis of ADP that had been incubated with
the reservoir solution used for crystallization for
24 h at 6 °C showed that a small amount of ADPwas
hydrolyzed to AMP within this time-span (results
not shown).
155Crystal Structure of Human DDX3XA fluorescence-based stability assay was used to
elucidate why AMP was preferably bound to
DDX3X(V168-G582).25 The thermostability of
DDX3X(V168-G582) was monitored in the presence
of different nucleotides/nucleotide analogues
(8 mMATP, ADP or AMP, and 4mMANP, AMPPCP
or ATPγS). This stability assay showed that the only
nucleotide that gave a small increase in the thermal
stability of DDX3X(V168-G582), by ∼2–4° deg.C
was AMP (Figure 5(b) and results not shown).
Altogether, the data suggest that DDX3X(V168-
G582) is stabilized by AMP and that the protein
crystallized with contaminating AMP that was
present in the nucleotide stock and by the sponta-
neous hydrolysis of small amounts of ADP to AMP.Discussion
The family of RNA-binding DExD-box helicases
displays a relatively high level of sequence similar-
ity and contains nine signature motifs that are
present in all known sequences.1 The general
consensus is that specificity of DExD-box helicases
is obtained by amino acid sequences that flank
conserved domains 1 and 2. However, some
sequence divergence is present within the conserved
helicase core. One such divergent region is found
between nucleotide-binding motif I and RNA-
binding motif Ia in domain 1; for example, human
eIF4A, its isoform eIF4AIII and UAP56 all contain 25
amino acid residues between conserved amino acids
GKT and TRELA in motifs I and Ia, respectively,
whereas DDX3X and its male germ cell-specific copy
DDX3Y contain 43 residues (Figure 3). The structure
presented here shows that the insertion forms a helix
that positions a positively charged loop in close
proximity to a putative RNA ligand (Figure 4) and
we speculate that this unique feature is an important
determinant in RNA–substrate interaction by
DDX3X/Y. This unique structural feature, together
with the particular physiochemical properties of this
segment, should be considered in drug design
efforts; especially since it most likely is directly
involved in substrate binding.
It is somewhat surprising that AMP was found in
the nucleotide-binding pocket of DDX3X(V168-
G582) but, clearly, the structure presented here
shows that AMP-binding to a DEAD-box helicase
containing the conserved helicase core is possible
and not a peculiarity that is specific to constructs
comprising only conserved domain 1, i.e. domain 1
of the T. thermophilus Hera helicase,23 where
structural determinants for correct formation of the
nucleotide-binding pocket may be lacking. The
results presented here suggest that the monopho-
sphate form of the nucleotide is found in the
nucleotide-binding pocket, since it has a stabilizing
effect on DDX3X(V168-G582). The physiological
relevance of this observation awaits further elucida-
tion, since AMP should not be formed during the
ATP hydrolysis cycle and cellular concentrations of
ATP and ADP should be in large excess of AMP.A recent characterization of the ATPase and
helicase activity of full-length DDX3X indicates
that DDX3X displays relaxed substrate specificity
with regards to the base and sugar moiety, and the
authors suggest that this relaxed specificity could be
used in the development of specific inhibitors.26
However, the structure presented here shows that
the interaction of DDX3X(V168-G582) with the base
and ribose is similar to that of other DExD-box
helicases and it does not give any clues to the
suggested relaxed substrate specificity described in
the other study.26
The conformation of the P-loop differs slightly in
DDX3X(V168-G582) compared to the other pub-
lished structures. It has been postulated that this
loop is a molecular sensor of bound nucleotide, since
structures that contain nucleotide generally have a
more open conformation of the P-loop than those
lacking nucleotide.1 However, the conformations of
the P-loops in DDX3X(V168-G582) and in Hera
helicase are neither open or fully closed, suggesting
that there are more than two possible states.23
Therefore, we favor a model where the energetics
of none of the P-loop conformations is very much
favored, apart from the requirement to provide a
binding pocket large enough for the ligand.
In vivo and in vitro mutagenesis studies have been
performed by others to investigate the role of
specific amino acids in the nucleotide-binding
pocket. Mutation of lysine 230 to glutamate and
serine 382 to leucine reduces the ATPase and RNA-
unwinding activity in vitro and abolishes expression
from RRE-containing mRNAs in vivo.9 In DDX3X
(V168-G582), the nitrogen atom of lysine 230 is
approximately 6 Å from the oxygen atom on the α-
phosphate group of AMP, suggesting that the β/γ
phosphate group on a putative ADP/ATP molecule
could interact with lysine 230. Serine 382 in the
conserved SAT/motif III is further away from the α-
phosphate group (13 Å) and it is unlikely that there
would be an interaction with a putative β/γ
phosphate group. Instead, it has been suggested
that a small reduction in ATP and RNA-binding
affinity results in a loss of helicase activity.1
Mutation of threonine 204 to glutamate, which is
located in the Q motif, inactivates hamster-DDX3X,
which is more than 95% identical with the human
protein. It was shown recently that threonine 204 is
phosphorylated by cyclin B in vitro, and it was
suggested that phosphorylation would lead to an
inactive protein.27 The structure rationalizes the
observed mutation data, since a glutamate or phos-
phorylation at residue 204 would result in steric
clashes in the near vicinity of the adenine base,
which would interfere with nucleotide binding.
Surprisingly, DDX3X(V168-G582) displays no
ATPase activity in the presence of different single-
stranded or partially double-stranded RNA sub-
strates. In contrast, the full-length protein displays
ATPase activity in the presence of RNA substrates.9,26
Similarly, several other recombinant DExD/H-box
helicases show reduced ATPase/helicase activity
when flanking sequences are removed. For example,
156 Crystal Structure of Human DDX3Xthe ATPase activity of UAP56 is reduced by half by
removing 46 residues from the N terminus that are
specific toUAP56,11 and the helicase activity ofDP103
(DDX20) is dependent on C-terminal flanking
sequences that are not part of the conserved helicase
core.28 In contrast, constructs of other DExD/H-box
helicases comprising only the conserved helicase core
display ATPase activity in vitro; e.g. the yeast splicing
factor Prp22p.29 It is not clear to uswhy some helicase
cores display ATPase/helicase activity and others do
not. What is becoming evident is that, although
conserved domains 1 and 2 show high levels of
sequence conservation and similar structural folds,
much remains to be discovered about how the
helicase core structure is linked to activity.
We find it most likely that the lack of ATPase
activity in DDX3X(V168-G582) is due to missing N-
terminal and/or C-terminal sequences. Since, when
doing a search against the Pfam family database,30
the flanking sequences contain no detectable
domain architecture, it is more difficult to speculate
how these additional sequences give specificity
and/or activity. However, it is not unlikely that
these represent natively disordered regions, since
the first 130 and last 90 amino acid residues of
DDX3X are predicted to be disordered by the
protein dynamic disorder server DISOPRED.31
These so-called intrinsically unstructured regions
could fold only upon interaction with other protein
domains or RNA substrates.32,33
As mentioned above, ATPases in general, includ-
ing RNA and DNA helicases, have been proposed as
an interesting protein family in terms of potential
novel drug targets.34 In particular, DDX3X has been
identified as a possible antiviral drug target, since it
is involved in the transport of HIV mRNAs from the
nucleus to the cytoplasm.10,35 The three-dimensional
structure presented here provides important infor-
mation to strengthen a drug discovery program
directed towards DDX3X. Putative drug-binding
sites include the nucleotide-binding pocket and the
substrate recognition site. As shown here, the
nucleotide-binding pocket of DDX3X is highly
similar to those of other DExD-box helicases and it
is probably not trivial to obtain specific inhibition of
a particular DExD-box helicase by targeting the
nucleotide-binding pocket.35 However, specific inhi-
bitors have been developed that are directed
towards the nucleotide-binding pocket of other
ATPases, such as the kinases, and it may prove a
successful way ahead for the DExD-box helicases. It
should be investigated whether the propensity to
bind mononucleotides by certain DExD-box heli-
cases such as DDX3X(V168-G582) and domain 1 of
the Hera helicase can be utilized in the design of
nucleotide inhibitors. Another approach to inhibit a
particular helicase such as DDX3X may be to target
its unique sequences of potential importance for
substrate recognition/activation, such as the
DDX3X/Y-specific insertion described here. It is
thus necessary to elucidate the structures and
functions of these unique features to obtain more
information on substrate interaction and helicaseactivation, and to identify potential sites for drug
intervention, for a given DExD-box helicase.Materials and Methods
Cloning of the ddx3x gene
Eleven different constructs were amplified from the
ddx3x gene (gi:33873845) and moved into the pET-based
pNIC-Bsa4 vector by ligation-independent cloning. All
constructs contained a removable His tag at the N
terminus.Expression of the ddx3x gene and purification of
DDX3X protein
The plasmid constructs were transformed into the strain
BL21(DE3) and tested on a small scale for expression before
attempting large-scale expression and purification of
protein. The large-scale culture, in Terrific Broth supple-
mented with 8 g/l of glycerol, grew at 37 °C. At an ab-
sorbance at 600 nm between 1 and 2 the temperature was
lowered to 18 °C and recombinant protein production was
induced by addition of isopropyl-β-d-thiogalactopyrano-
side (0.5 mM final concentration) and continued for 18 h at
18 °C.
Cells were harvested by centrifugation and the cell
pellet was dissolved in buffer 1 (50 mM sodium phosphate
(pH 7.5), 500 mMNaCl, 10% (v/v) glycerol, 0.5 mMTris(2-
carboxyethyl)-phosphine (TCEP)) with 10 mM imidazole
and Complete EDTA-free protease inhibitor according to
the manufacturer's instructions (Roche Biosciences).
Before lysis, 20 units/ml of Benzonase (Novagen) was
added and lysis was achieved by sonication. Cell debris
was removed by centrifugation and the soluble fraction
was filtered through a syringe filter (0.45 μm pore size).
DDX3X protein was purified on an Äkta purifier system
essentially as described,36 with the following minor
modifications: the lysate was loaded onto a 1 ml HisTrap
FF crude column (Amersham Biosciences), non-bound
protein was removed by washing with buffer 1 containing
25 mM imidazole and affinity-bound protein was eluted
with buffer 1 containing 500mM imidazole. Eluted protein
was loaded onto a Superdex 200 16/60 gel-filtration
column (Amersham Biosciences) in buffer 2 (20 mM
Hepes (pH 7.5), 500 mM NaCl, 10% glycerol, 0.5 mM
TCEP); DDX3X migrated as a monomer in this column.
The N-terminal His tag was removed by incubating
400 μMDDX3Xwith a His-tagged TEV protease at a molar
ratio of 1:50 for 18 h at 4 °C. After removal of TEV protease
and the His tag, DDX3X was concentrated to 480 μM,
samples were flash-frozen in liquid nitrogen and stored at
−80 °C. SDS-PAGE analysis showed that the protein was
more than 90% pure (results not shown), and the correct
mass of the different DDX3X constructs was verified by
mass spectrometry (results not shown).Thermal stability-shift assay
Changes in thermal stability due to ligand binding were
measured by monitoring the intensity from the environ-
mentally sensitive dye, SyproOrange (Molecular Probes,
Eugene, OR) while heating the samples from 20–90 °C in a
Bio-Rad iCycler RT PCR.25 DDX3X(V168-G582) protein
(4 μM final concentration) was diluted in 50 mM Tris–HCl
Table 1. Data collection statistics from XDS and
refinement
A. Data collection
Beamline ESRF ID23-1
Wavelength (Å) 1.072
Space group P3121
Cell parameters:
a (Å) 67.3
b (Å) 67.3
c (Å) 253.5
α (deg.) 90
β (deg.) 90
χ (deg.) 120
Resolution (Å) 15.0–2.20 (2.30–2.20)
No. unique reflections 32,841
Redundancy 10.6
Completeness (%) 99.2 (98.8)
Rsym (%) 7.2 (47.6)
I/σ 19.3 (5.7)
B. Refinement statistics
Resolution (Å) 15.0–2.20
No. unique reflections 32,841
No. reflections in test set 1751
Rwork (%) 18.1
Rfree (%) 21.6
RMSD from ideala
Bond lengths (Å) 0.020
Bond angles (deg.) 1.74
Values in parentheses refer to values in the highest resolution
shell. There was no residue in the disallowed regions of the
Ramachandran plot, as calculated using PROCHECK.44
a Ideal values from.45
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2 mM TCEP, before addition of nucleotides ATP, ADP, and
AMP to a final concentration of 8 mM or ATP analogues
ANP, AMPPCP, and ATPγS to a final concentration of
4 mM, and 1000-fold diluted SyproOrange. Fluorescence
was measured from 20–89.6 °C and the thermal shift was
determined as described.37
ATPase assay
The ATPase assay was performed essentially as
described,38 with the following modifications: 0.1–
1.4 μM DDX3X(V168-G582) was incubated with 1–10 μg
of poly(U), poly(A), poly(C) or in vitro transcribed RNA
mimicking stem–loop IIB in RRE (see below)39 in 50 mM
Tris–HCl (pH 7.5 at 37 °C) or 50 mM Hepes–KOH (pH 6.2
at 37 °C), 50 mMNaCl, 2 mM TCEP, 2 or 5 mMMgCl2 and
0.5 mMATP (Sigma Aldrich). In an attempt to obtain some
activity, chloride was omitted from the reactions, the
concentration of salt was varied between zero and
200 mM, and the assay was run also at pH 5 and pH 9.
The reaction mixtures, total volume of 100 μl, were
incubated at 37 °C for 1 h. A colorimetric assay based on
the malachite green/molybdate reaction was used to
detect the release of free phosphate.11 A 200 μl portion of
Biomol green reagent (Biomol International) was added to
the reaction mixtures, and absorbance was measured at
620 nm after incubation for 25 min at room temperature.
Alternatively, formation of (α-32P)-labeled ADP/AMP
was tested by incubating 0.8 μM DDX3X(V168-G582) in
50 mM Tris–HCl (pH 7.5), 50 mM NaCl, 5 mM MgCl2,
1 mM DTT, with 1 μCi of [α-32P]ATP (Amersham
BioSciences) and 0.1 mM ATP (Sigma Aldrich). The
reaction mixture, total volume of 20 μl, was incubated at
37 °C for 1 h and 3 μl of 0.5 M EDTAwas added to stop the
reaction. Possible formation of α-labeled AMP was
monitored by loading 2 μl of the reaction mixtures onto
PEI TLC plates (Macherey & Nagel), and chromatography
was carried out in 1 M formic acid, 0.5 M lithium chloride
for 3 h at room temperature. Radioactive nucleotides were
visualized by autoradiography using a phosphoimager or
HyperfilmMP (Amersham Bioscience). [α-32P]AMP (Amer-
sham Biosciences) was run as a control on the TLC plates.
In vitro transcription
The short RNA mimicking stem–loop IIB in RRE was
transcribed with a Mega-Short transcription kit (Ambion)
following the manufacturer's instructions. The two com-
plementary oligonucleotidess used as templates for in vitro
transcription had the following sequence (transcribed
region underlined): 5′TAATACGACTCACTATAGGGAA-
CGGGCGCAGAATCTGACGGTACGTTT3′ and 5′AAA-
CGTACCGTCAGATTCTGCGCCCGTTCCCTATAGT-
GAGTCGTATTA3′.
Analysis of the purity of the ADP
The purity of the ADP used in the crystallization
experiments was determined by HPLC using a Supelcosil
LC-18-T, 5 μm column (25 cm×4.6 mm) and isocratic
elution with 0.1 M KH2PO4 (pH 6.0) and a flow-rate of
1 ml/min. ADP (100 μl of 100 μM solution) eluted at
5.7 min and AMP (100 μl of 100 μM solution) eluted at
9.6 min. Equal volumes of ADP solution and the reservoir
solution used in crystallization (100mMTris-HCl (pH 8.0),
1.75 M sodium formate) were mixed and incubated for24 h at 6 °C before the nucleotide content was determined
as described above. This analysis showed that a small
amount of ADP was hydrolyzed to AMP in 24 h (2%
corresponding to 400 μM).
Crystallization and data collection
DDX3X(V168-G582) crystals were grown using vapor
diffusion at 4 °C by mixing equal amounts of protein
solution (21 mg/ml or 446 μM) containing 20 mM ATPγS
or 20 mM ADP and 20 mM MgCl2 and reservoir solution
containing 100 mM Tris-HCl (pH 8.0), 1.75 M sodium
formate). Crystals appeared after one day and had
reached their maximal size in 12 days (approximately
300 μm×100 μm×50 μm). Unsuccessful attempts were
made to crystallize DDX3X(V168-G582) with ANP,
AMPPCP and without nucleotide. As cryoprotectant,
motherliquor supplemented with of 20% PEG 400, 10%
glycerol and 300 mM NaCl was added to the drop, then
crystals were harvested and flash-cooled in liquid nitro-
gen. The diffraction data were collected at beamline ID23-
1 at the ESRF synchrotron facility in Grenoble, France. All
data were indexed and integrated in space group P3121
with the XDS package.40 The cell parameters are
a=b=67.288 Å, c=253.470 Å, α=β=90°, χ=120°.
Structure solution and refinement
The structure was solved by molecular replacement
using the two domains separately. The N-terminal RecA-
like domain of DjVLGB (PDB entry 1WRB) was used as
the search model for domain 1, and the ATP-dependent
RNA helicase VASA (PDB entry 2DB3) was used for
158 Crystal Structure of Human DDX3Xdomain 2. The asymmetric unit contains one protein
monomer. Refmac was used for refinement,41 and Coot
was used for model building.42 TLS refinement using four
TLS groups as suggested by tlsmd‡ was used with
Refmac.43 In the refinement, data in the interval 15–
2.20 Å resolution were used and the progress of refine-
ment was followed by decreasing R and Rfree values. At
the end of the refinement, R=0.1887 and Rfree=0.2182. The
final model of DDX3X(v168-G582) starts at valine 168 and
ends at tyrosine 580. Residues 407–410, 535–536 and 581–
582 are disordered and are not visible in the electron
density. A Ramachandran plot shows 98% of all residues
in favored regions and no outlier in the disallowed
regions. The data collection and refinement statistics are
given in Table 1.
Protein Data Bank, accession code
Coordinates for the crystal structure have been depos-
ited in the Protein Data Bank with accession code 2I4I.Acknowledgements
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